20 years after the human genome was first sequenced, dangerous gene myths abound
By Philip Ball,
The Guardian
| 06. 09. 2021
Twenty years ago, the science journal Nature published the first draft of the human genome: the sequence of chemical “letters” on the gene-bearing DNA of our chromosomes. The Human Genome Project (HGP) had laboured for a decade to read this coded information. In a White House press conference in 2000, Francis Collins, who led the project as director of the US National Human Genome Research Institute, waxed biblical, calling the human genome “our own instruction book, previously known only to God”.
The HGP has huge potential benefits for medicine and our understanding of human diversity and origins. But a blizzard of misleading rhetoric surrounded the project, contributing to the widespread and sometimes dangerous misunderstandings about genes that now bedevils the genomic age.
So far, there have been few attempts to set the record straight. Even now, the National Human Genome Research Institute calls the HGP an effort to read “nature’s complete genetic blueprint for building a human being” – the “book of instructions” that “determine our particular traits”. A genome, says the institute, “contains all of the information needed to...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...